HCBE Faculty Articles
ORCID
Yuliya Yurova0000-0003-4524-3471
Document Type
Article
Publication Title
Journal of Translational Medicine
ISSN
1479-5876
Publication Date
3-14-2015
Abstract/Excerpt
Background: While the concept of angiogenesis blockade as a therapeutic intervention for cancer has been repeatedly demonstrated, the full promise of this approach has yet to be realized. Specifically, drugs such as VEGF-blocking antibodies or kinase inhibitors suffer from the drawbacks of resistance development, as well as off-target toxicities. Previous studies have demonstrated feasibility of specifically inducing immunity towards tumor endothelium without consequences of systemic autoimmunity in both animal models and clinical settings.
Method: Placenta-derived endothelial cells were isolated and pretreated with interferon gamma to enhance immunogenicity. Syngeneic mice received subcutaneous administration of B16 melanoma, 4 T1 mammary carcinoma, and Lewis Lung Carcinoma (LLC), followed by administration of control saline, control placental endothelial cells, and interferon gamma primed endothelial cells (ValloVaxâ„¢). Tumor volume was quantified. An LLC metastasis model was also established and treated under similar conditions. Furthermore, a safety analysis in non-tumor bearing mice bracketing the proposed clinical dose was conducted.
Results: ValloVaxâ„¢ immunization led to significant reduction of tumor growth and metastasis as compared to administration of non-treated placental endothelial cells. Mitotic inactivation by formalin fixation or irradiation preserved tumor inhibitory activity. Twenty-eight day evaluation of healthy male and female mice immunized with ValloVaxâ„¢ resulted in no abnormalities or organ toxicities.
Conclusion: Given the established rationale behind the potential therapeutic benefit of inhibiting tumor angiogenesis as a treatment for cancer, immunization against a variety of endothelial cell antigens may produce the best clinical response, enhancing efficacy and reducing the likelihood of the development of treatment resistance. These data support the clinical evaluation of irradiated ValloVaxâ„¢ as an anti-angiogenic cancer vaccine.
DOI
https://doi.org/10.1186/s12967-015-0441-0
Document Number
90
Funding Information
The work in this publication was funded by Batu Biologics.
NSUWorks Citation
Ichim, Thomas E.; Li, Shuang; Ma, Hong; Yurova, Yuliya V.; Syzmanski, Julia S.; Patel, Amit N.; Kesari, Santosh; Min, Wei-Ping; and Wagner, Samuel C., "Induction of tumor inhibitory anti-angiogenic response through immunization with interferon gamma primed placental endothelial cells: ValloVaxâ„¢" (2015). HCBE Faculty Articles. 1117.
https://nsuworks.nova.edu/hcbe_facarticles/1117
